脑脊液生物标志物检测在阿尔茨海默病诊断中值得注意的若干问题  

Cerebrospinal fluid examination in the diagnosis of Alzheimer's disease on several issues worthy of attention

作　　者：安小娟 孟丹 蔡攀 AN Xiaojuan;MENG Dan;CAI Pan(Graduate School of Zunyi Medical university,Zunyi,Guizhou 563000,China;Affiliated Hospital of Zunyi Medical university,Zunyi,Guizhou 563000,China.)

机构地区：[1]遵义医科大学研究生院,贵州遵义563000 [2]遵义医科大学第三附属医院,贵州遵义563000

出　　处：《阿尔茨海默病及相关病杂志》2022年第2期166-169,共4页Chinese Journal of Alzheimer's Disease and Related Disorders

基　　金：贵州省教育厅青年科技人才成长项目;基于13C-亮氨酸标记的阿尔茨海默病模型鼠Aβ代谢途径及针刺效应研究,黔科合KY字[2017]186。

摘　　要：生物标志物检测在阿尔茨海默病诊断中至关重要,其中脑脊液生物标志物检测因其高度的敏感性、特异性和可操作性,在临床上较示踪剂正电子发射计算机断层显像(positron emissiontomography,PET)更易普及。但目前国内医院脑脊液生物标志物检测大多依赖于院外的检测机构,且无统一的检测规范和标准,常导致检测结果误差较大,因此本文就脑脊液生物标志物检测过程中值得注意的若干问题作一概述,以期最大限度的缩小脑脊液生物标志物在临床检测中的误差,充分发挥其在AD早期诊断中的重要价值。Detection of biomarkers is crucial in the diagnosis of Alzheimer’s disease, in which the examination of cerebrospinal fluid biomarkers is easier to be carried out than the tracer PET in clinical practice because of its high sensitivity, specificity and operability. However,at present, the domestic cerebrospinal fluid biomarkers testing is mostly affected by out-of-hospital testing institutions, and there is no unified detection criterion and standard,, resulting in large testing errors. Therefore, this article summarizes several noteworthy issues in the collection and detection of cerebrospinal fluid in order to minimize the error in the clinical detection of cerebrospinal fluid biomarkers and give full play to the important value of cerebrospinal fluid biomarkers examination in the early diagnosis of AD.

关 键 词：阿尔茨海默病 生物标志物 脑脊液检测 

分 类 号：R741[医药卫生—神经病学与精神病学]